Efficacy and safety of sucroferric oxyhydroxide on hemodialysis patients
Not Applicable
Completed
- Conditions
- Chronic kidney disease
- Registration Number
- JPRN-UMIN000032867
- Lead Sponsor
- Department of Nephrology, hypertension and Endocrinology, Nihon University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
(1) age < 20 years or > 85 years; (2) history of severe heart failure, angina, myocardial infarction, or stroke within the past 6 months; (3) presence of infectious disease, malignant tumors, or treatment with steroids or immunosuppressants; (4) current hospitalization; and (5) treatment with ferric citrate hydrate within the past 6 months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FGF23 levels and anemia-related parameters
- Secondary Outcome Measures
Name Time Method Ca, P, intact-PTH levels safety